Ariceum Therapeutics Commences Phase 1 Clinical Trial in Patients with Recurrent Glioblastoma

Ariceum Therapeutics United States of America Germany United Kingdom Switzerland Australia

Novel iodine radiolabelled PARP inhibitor (rPARPi) entering clinical development in Phase 1 trial to assess safety and early efficacyDose escalation study followed by expansion cohorts in recurrent glioblastoma with potential to move into primary glioblastomaView original content:https://www.prnewswire.co.uk/news-releases/ariceum-therapeutics-commences-phase-1-clinical-trial-in-patients-with-recurrent-glioblastoma-302205350.html